Novo's Big 2030 Pitch Gets a Small Reception - Moby THE GIST Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Novo laid out an ambitious pipeline, more patients and billions in future drug sales, but investors wanted a clearer answer to the question hanging over the company: what replaces semaglutide when competition and patents catch up? The shares tumbled as management's long-term growth targets proved too broad to reassure a market already worried about Eli Lilly, pricing pressure and recent clinical setbacks.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.